Prediction of therapeutic value of new drugs approved by health Canada from 2011−2020: A cross-sectional study

ABSTRACT:

Objectives

To examine whether a combination of three characteristics of new drugs – review type, outcome of premarket trials (surrogate or clinical) and first-in-class is associated with significant therapeutic value.

Design

Cross-sectional analysis of new drugs approved by Health Canada from January 1, 2011 to December 31, 2020.

Setting

Canada.

Participants

New drugs approved by Health Canada for which therapeutic evaluations, trial outcomes and first-in-class status was available.

Main outcome measures

Distribution of therapeutic value (major, moderate, little to no) depending on how many of the three characteristics were present for each drug.

Results

Health Canada approved 340 drugs of which 243 had data available for analysis. If a

SUBMITTER:  

PROVIDER: S-EPMC10225954 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature